Insulet (NASDAQ:PODD – Get Free Report) was downgraded by investment analysts at Stifel Nicolaus from a “buy” rating to a “hold” rating in a research report issued on Wednesday, MarketBeat reports. They currently have a $165.00 target price on the medical instruments supplier’s stock, down from their previous target price of $180.00. Stifel Nicolaus‘s target price would indicate a potential upside of 13.53% from the stock’s previous close.
Other equities analysts have also recently issued research reports about the stock. BTIG Research cut shares of Insulet from a “buy” rating to a “neutral” rating in a research report on Thursday, August 6th. Raymond James Financial reaffirmed an “outperform” rating and issued a $180.00 price target on shares of Insulet in a report on Thursday, August 6th. Barclays increased their price target on shares of Insulet from $150.00 to $165.00 and gave the company an “equal weight” rating in a research report on Friday, November 6th. Sanford C. Bernstein raised their price objective on shares of Insulet from $175.00 to $200.00 and gave the stock an “outperform” rating in a research note on Thursday, November 5th. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of Insulet in a research note on Monday, September 21st. Eleven analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $185.04.
Read Our Latest Report on PODD
Insulet Trading Up 0.0%
Shares of PODD stock opened at $145.34 on Wednesday. The stock has a market cap of $10.08 billion, a P/E ratio of 23.67, a P/E/G ratio of 1.11 and a beta of 1.06. The company has a quick ratio of 1.83, a current ratio of 2.51 and a debt-to-equity ratio of 0.60. Insulet has a fifty-two week low of $126.40 and a fifty-two week high of $354.88. The business has a fifty day simple moving average of $142.16 and a 200-day simple moving average of $172.43.
Insulet (NASDAQ:PODD – Get Free Report) last released its quarterly earnings data on Wednesday, November 4th. The medical instruments supplier reported $1.99 EPS for the quarter, topping the consensus estimate of $1.59 by $0.40. The business had revenue of $842.00 million for the quarter, compared to analyst estimates of $832.63 million. Insulet had a net margin of 13.44% and a return on equity of 31.76%. The business’s revenue for the quarter was up 19.2% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.24 EPS. On average, analysts forecast that Insulet will post 6.76 earnings per share for the current fiscal year.
Institutional Trading of Insulet
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PODD. BlackRock Inc. purchased a new position in Insulet in the 2nd quarter valued at about $1,018,582,000. Soleus Capital Management L.P. boosted its stake in shares of Insulet by 64.6% during the 3rd quarter. Soleus Capital Management L.P. now owns 1,726,500 shares of the medical instruments supplier’s stock worth $225,256,000 after purchasing an additional 677,500 shares during the last quarter. Arrowstreet Capital Limited Partnership grew its holdings in shares of Insulet by 462.7% during the first quarter. Arrowstreet Capital Limited Partnership now owns 1,229,928 shares of the medical instruments supplier’s stock worth $258,088,000 after buying an additional 1,011,369 shares in the last quarter. Worldquant Millennium Advisors LLC grew its holdings in shares of Insulet by 104.6% during the third quarter. Worldquant Millennium Advisors LLC now owns 545,615 shares of the medical instruments supplier’s stock worth $71,186,000 after buying an additional 278,926 shares in the last quarter. Finally, Man Group plc purchased a new stake in shares of Insulet during the second quarter worth about $78,746,000.
Insulet Company Profile
Insulet Corporation is a medical device company focused on insulin delivery for people with diabetes. Founded in 2000, the company developed the Omnipod platform, which delivers insulin through a small, wearable pod without the tubing used by many traditional insulin pumps. Its products include Omnipod DASH and Omnipod 5, an automated insulin delivery system that can adjust insulin delivery based on glucose readings from compatible continuous glucose monitors. Insulet also provides related controllers, mobile app features, supplies and customer support.
Further Reading
- Five stocks we like better than Insulet
- Disney Has the Magic Touch: Dividend Growth and Buybacks Could Fuel a Breakout
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.
